At the fourth Biennial International Symposium on AMD, held October 21-22, 2016 in Boston, more than 200 clinicians, researchers, trainees, and industry representatives discussed current AMD topics and the challenges that lay ahead. One of the central themes of this year’s symposium was the need for a more precise stratification of the disease.
A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin (cholesterol-lowering medication) had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the developed world, and though effective treatments are available for the wet AMD, they are currently lacking for the more-prevalent dry form.
Drawing nearly 250 clinicians, researchers, trainees, and industry representatives from around the world, the Third International Biennial Symposium on AMD, which was held October 24–25, 2014 and co-chaired by Chief and Chair of Ophthalmology, Joan Miller, MD, FARVO, and AMD Center of Excellence co-directors Patricia D’Amore, PhD, MBA, FARVO and Ivana Kim, MD, had special significance because it followed the 2014 António Champalimaud Vision Award, which recognized the development of antiangiogenic therapies for AMD and other retinal diseases. Five members of the HMS Department of… Read more about Eyes on the Complement System at the Third International Biennial Symposium on AMD